<DOC>
	<DOCNO>NCT02253160</DOCNO>
	<brief_summary>The purpose prospective , randomize , cross-over , multi-center study evaluate performance Spectra Optia Apheresis System 's CMNC Collection Procedure , compare COBE Spectra Apheresis System 's MNC Procedure mobilize healthy donor . Subject safety evaluate begin mobilization , throughout collection procedure day follow last collection .</brief_summary>
	<brief_title>An Evaluation Spectra Optia CMNC Collection Procedure</brief_title>
	<detailed_description>This prospective , randomize , cross-over , multi-center study evaluate performance Spectra Optia system 's CMNC Collection Procedure , compare COBE Spectra system 's MNC Procedure mobilize healthy donor . Up 60 subject may consent meet enrollment target 20 complete subject . Eligible subject randomize receive either Spectra Optia CMNC COBE Spectra MNC collection procedure first , follow opposite following day . Study participation 14 day : 7-day screening period , four day mobilization , one day first MNC collection additional dose mobilization , one day second MNC collection , safety follow-up following day . Subject safety evaluate begin mobilization , throughout collection procedure day follow second collection .</detailed_description>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . ≥ 18 ≤ 50 year age 2 . Healthy blood donor criterion define American Associate Blood Banks ( AABB ) ) Note : Subjects defer volunteer donation travel restriction , piercings tattoo may participate study 3 . Adequate dual peripheral venous access 4 . Acceptable prescreening laboratory result prior MNC mobilization specify : ) WBC 3,500 10,800/µL b ) Hematocrit 38 % 56 % c ) Platelets 150,000 400,000/µL ) Coagulation test : i. PT 9.0 13.0 second ii . PTT 23.4 41.8 second e ) Serum electrolytes : i. Potassium 3.6 5.1 mmol/L ii . Serum Calcium 8.5 mg/dL 10.3 mg/dL f ) Renal function : Serum creatinine ≤ 1.5 mg/dL NOTE : two laboratory result may fall range list , judgment investigator , constitute significant risk subject . 5 . Liver function : alanine aminotransferase ( ALT ) &lt; 1.5 time upper limit normal 6 . Willing avoid pregnancy least 48 hour follow last GCSF injection 1 . If male , willing use condom sexual relation female partner 48 hour follow last GCSF injection 2 . If female childbearing potential , willing use medically acceptable contraceptive 48 hour follow last GCSF injection 7 . Given write informed consent 1 . Previous MNC collection failure 2 . Known hypersensitivity condition prevents use anticoagulant 3 . Known hypersensitivity condition prevents use GCSF 4 . Known hemoglobinopathy include sickle cell trait disease 5 . History use past week anticipate need lithium 6 . Concurrent enrollment another clinical study could impact result participation study 7 . Active infection serious underlie medical condition contraindicates apheresis 8 . Women pregnant lactate 9 . Known history significant head trauma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>MNCs</keyword>
	<keyword>Mononuclear Cells</keyword>
	<keyword>Apheresis</keyword>
	<keyword>Spectra Optia</keyword>
</DOC>